Blood Cancer United Inc 2022 SR
The report highlights the bold progress made by The Leukemia & Lymphoma Society (LLS) in fiscal year 2022. LLS supported the FDA approval of 14 new blood cancer treatment options and invested significantly in pediatric research through the launch of The Dare to Dream Project and the PedAL Master Clinical Trial. Additionally, the organization provided over $385 million in financial assistance to more than 75,000 patients and successfully advocated for key healthcare policies, including a $2,000 annual cap on Medicare out-of-pocket drug costs.
Company: Blood Cancer United Inc
Sector: Healthcare & social services
Country: United States
Year: 2022
Type: SR
Pages: 68
Back to company
Blood Cancer United Inc
Annual Report
The report highlights the bold progress made by The Leukemia & Lymphoma Society (LLS) in fiscal year 2022. LLS supported the FDA approval of 14 new blood cancer treatment options and invested significantly in pediatric research through the launch of The Dare to Dream Project and the PedAL Master Clinical Trial. Additionally, the organization provided over $385 million in financial assistance to more than 75,000 patients and successfully advocated for key healthcare policies, including a $2,000 annual cap on Medicare out-of-pocket drug costs.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jul 1, 2021 - Jun 30, 2022
Fiscal Year
2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
No data available